Oncostatin M Induction of Monocyte Chemoattractant Protein 1 (MCP-1) in Human Epidermal Keratinocytes Is Inhibited by Anti-Oncostatin M Receptor ß Monoclonal Antibody KPL-716

Carl D. Richards,[1] Rohan Gandhi,[2] Fernando Botelho,[1] Lilian Ho,[1] John F. Paolini[2]

[1]McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada; [2]Kiniksa Pharmaceuticals Corp., Lexington, Massachusetts, USA

BACKGROUND

- Oncostatin M (OSM) is a member of the gp130 cytokine family, including leukemia inhibitory factor (LIF) and interleukin (IL)-31, and is involved in TH2 inflammation, epidermal integrity, and fibrosis[1]
- OSM regulates extracellular matrix remodeling by altering the network of matrix metalloproteinases (MMPs), their inhibitors (tissue inhibitors of metalloproteinases [TIMPs]), other enzymes, and chemokines[1]
- Elevated OSM protein levels and mRNA have been documented in various inflammatory diseases, including rheumatoid arthritis, asthma, pulmonary fibrosis, and atopic dermatitis[1-5]
- OSM interacts with 2 receptors in humans[1]:
  - Type 1 receptor: LIF receptor complex (LIFRα/gp130)
  - Type 2 receptor: OSM receptor complex (OSMRβ/gp130)
- KPL-716 is a fully human monoclonal antibody that targets OSMRβ and simultaneously inhibits both IL-31 and OSM signaling[6]

OBJECTIVES

- To characterize the in vitro responses of human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF) to OSM in comparison to LIF and IL-31, using the chemokine monocyte chemoattractant protein 1 (MCP-1/CCL-2), which has roles in inflammatory responses[7]
- To assess the ability of KPL-716 in regulating MCP-1/CCL-2 responses in HEK and HDF cells

METHODS

- To assess the production of the chemokine MCP-1/CCL-2 and the intracellular signaling molecules called STATs (signal transducer and activators of transcription), cells were stimulated with human OSM, LIF, IL-31, transforming growth factor (TGF)-β, lipoprotein A (LPA), or combinations of IL-31 + OSM, IL-13 + OSM, and TGF-β + OSM for 30 minutes or 24 hours
- To characterize synergistic responses of OSM with human IL-4 or IL-13, cells were stimulated with 0–20 ng/mL of the cytokines alone or in combination with OSM, LIF, or IL-31 for 24 hours
- To determine antibody-mediated neutralization, cells were stimulated with 2x concentrated isotype control, KPL-716, or an anti–IL-31 receptor α (IL-31Rα) antibody (final concentrations of 0.1, 0.01, 0.001, and 0.0001 μg/mL); after 1-hour pre-incubation with antibody or media alone, OSM or OSM + IL-4 were added to cells and incubated for an additional 24 hours
- MCP-1/CCL-2 levels in supernatants were determined using DuoSet ELISA kits (R&D Systems, Minneapolis, MN)
- MCP-1/CCL-2 and receptor chain mRNAs were measured using Nanostring technology (Seattle, WA) or quantitative real-time polymerase chain reaction (qRT-PCR)
- Experiments shown are representative of ≥3 separate experiments
- Data are presented as mean ± standard error of the mean (SEM)
- One-way analysis of variance was used to determine statistical significance ($P<0.05$)

RESULTS

- OSM (50 ng/mL) significantly induced MCP-1/CCL-2 protein levels and mRNA at 24 hours (**Figure 1**)
- In HEK cells, OSM induced activation of STAT3 and STAT1 as measured by immunoblots for phosphorylated forms (pSTAT) (**Figure 2**)
  - Neither LIF nor IL-31stimulation (at higher concentrations of 100 ng/mL) induced detectable pSTAT3, pSTAT1, or pSTAT6 in HEK cells
- Similarly, in HDF cells, OSM induced phosphorylation of STAT3 and STAT1 (**Figure 3**)
  - LIF or IL-31 minimally activated pSTAT3 and pSTAT1 but with lower signals compared with OSM
- In both cell lines, OSM + IL-13 induced pSTAT1, 3, and 6 signals comparable to each cytokine alone, and TGF-β + OSM did not result in detectable differences from levels induced by OSM alone

Figure 1. OSM Strongly Induced MCP-1/CCL-2 Protein (A) and mRNA (B)



Data are mean ± SEM; two-way ANOVA; *P<0.05; **P<0.01; ****P<0.0001.

Figure 2. OSM Induces STAT Activation in HEK



Figure 3. OSM Induces STAT Activation in HDF



- A dose-dependent increase in MCP-1/CCL-2 production was observed for IL-4 or IL-13 in combination with OSM in both HEK and HDF cells (**Figure 4**)
  - IL-4 or IL-13 alone did not induce MCP-1/CCL-2 levels at any concentration assessed
  - Co-stimulation of IL-4 (or IL-13) with LIF or IL-31 did not result in any changes in MCP-1/CCL-2 levels
- In HEK cells, OSM significantly induced mRNA for the receptor chains of type II IL-4 receptor (IL-4Rα/IL-13Rα-1) to 1000–2000 Relative Units (RU) and OSMRβ/gp130 to 1000–3000 RU (**Figure 5**)
  - Levels of IL-13Rα-2 or IL-2Rγ (type I IL-4 receptor) were very low (<40 RU, where 10 RU is considered non-detectable or at background levels)
  - Levels of LIFRα were very low and IL-31Rα was reduced (≤200 RU) compared with OSMRβ and gp130
- Analysis of mRNA from HDF cells showed the exact same trends as HEK cells (data not shown)

Figure 4. OSM Synergizes With IL-4 or IL-13 in Induction of MCP-1/CCL-2 in HEK and HDF



Data are mean ± SEM; two-way ANOVA; *P<0.05 vs control; †P<0.05 vs OSM alone.

Figure 5. OSM Stimulates mRNA for the Receptor Chains of Type II IL-4 Receptor and Type II OSM Receptor Complexes in HEK Cells



Data are shown as Nanostring counts corrected to 3 housekeeping genes (ACTB, PPIB, UBC).
Data are mean ± SEM; one-way ANOVA; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.

Effect of KPL-716 (anti-OSMRβ antibody) on HEK cells

- KPL-716 significantly attenuated the cellular MCP-1/CCL-2 response to OSM (**Figure 6**)
  - At concentrations of KPL-716 of 0.001 μg/mL and higher, MCP-1/CCL-2 levels were markedly reduced
- KPL-716 significantly reduced MCP-1/CCL-2 levels associated with the synergistic response to OSM and IL-4 at both concentrations of IL-4 (5 and 20 ng/mL; **Figure 7**)
- Anti-IL-31Rα or isotype control antibody had no significant effect on the OSM-induced or OSM + IL-4–induced responses at any concentration tested

Figure 6. KPL-716 Inhibits OSM-Induced MCP-1/CCL-2 in HEK Cells



Data are mean ± SEM; two-way ANOVA; **P<0.01, no antibody vs KPL-716 at concentration of 0.001–0.1 μg/mL.

Figure 7. KPL-716 Inhibits OSM + IL-4–Induced MCP-1/CCL-2 in HEK Cells



Data are mean ± SEM; two-way ANOVA; **P<0.01, no antibody vs KPL-716.

CONCLUSIONS

- OSM regulates expression of the pro-inflammatory chemokine MCP-1/CCL-2 by HEK and HDF cells
- OSM synergizes with typical TH2 cytokines (IL-4 and IL-13) to induce MCP-1/CCL-2 in these cells
- OSM induces mRNA expression of the Type II IL-4 receptor chains
- LIF and IL-31 did not synergize with IL-4 or with IL-13 to induce MCP-1/CCL-2 in HEK and HDF cells, suggesting a separate pathway for OSM signaling in these cells
- KPL-716, at low concentrations, reduced both the OSM induction and the synergistic OSM + IL-4 induction of MCP-1/CCL-2 protein production
- The potent inhibition of OSM activity by KPL-716 suggests therapeutic potential in TH2-mediated disease distinct from KPL-716 inhibition of IL-31 signaling

REFERENCES

1. Richards CD. *SRN Inflamm.* 2013;2013:512103. **2.** Hui W, et al. *Ann Rheum Dis.* 1997;56:184-7. **3.** Simpson JL, et al. *Exp Lung Res.* 2009;35:781-94. **4.** Boniface K, et al. *J Immunol.* 2007;178:4615-22. **5.** Mozaffarian A, et al. *J Immunol.* 2008;181:7243-53. **6.** Mikhak Z, et al. Presented at: 27th Congress of the European Academy of Dermatology and Venereology; September 12–16, 2018; Paris, France. **7.** Deshmane SL, et al. *J Interferon Cytokine Res.* 2009;29:313-26.

DISCLOSURES

This study is being sponsored by Kiniksa Pharmaceuticals Ltd. Medical writing assistance was provided by Peloton Advantage, LLC, an OPEN Health Company, funded by Kiniksa Pharmaceuticals Ltd.

For an e-Print and methodology for each figure, scan this QR code. Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the authors of this poster.